Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 19, 2025 08:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers

Weekly subcutaneous administration of sabirnetug was well-tolerated in the Phase 1 study Systemic exposure following subcutaneous administration supports further clinical development Development of...
March 12, 2025 08:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual Meeting

NEWTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid...
March 10, 2025 16:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

NEWTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble...
January 09, 2025 08:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings

Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer’s Disease supports continued development of sabirnetug (ACU193) for treatment of early Alzheimer’s disease (AD) Sabirnetug...
November 26, 2024 16:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference

NEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble...
November 12, 2024 07:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights

Expect ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, to complete enrollment in the first half of 2025Expect to announce topline...
November 11, 2024 16:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble...
November 06, 2024 16:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference

NEWTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble...
November 06, 2024 08:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality

NEWTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid...
November 05, 2024 16:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024

NEWTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic...